ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma
Authors
Keywords
-
Journal
Cells
Volume 9, Issue 3, Pages 647
Publisher
MDPI AG
Online
2020-03-09
DOI
10.3390/cells9030647
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Innate Biologies of Adaptive Antigen Receptors
- (2020) Adrian C. Hayday et al. Annual Review of Immunology
- Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers
- (2019) Daniel D. Waller et al. CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo
- (2019) Po-Jung Pan et al. Journal of Clinical Medicine
- Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model
- (2019) TAKASHI HIGUCHI et al. ANTICANCER RESEARCH
- PTHR1 May Be Involved in Progression of Osteosarcoma by Regulating miR-124-3p-AR-Tgfb1i1, miR-27a-3p-PPARG-Abca1, and miR-103/590-3p-AXIN2 Axes
- (2019) Shenglong Li et al. DNA AND CELL BIOLOGY
- An update on emerging drugs in osteosarcoma: towards tailored therapies?
- (2019) Claudia Maria Hattinger et al. EXPERT OPINION ON EMERGING DRUGS
- Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
- (2019) Zsolt Sebestyen et al. NATURE REVIEWS DRUG DISCOVERY
- Dynasore suppresses cell proliferation, migration, and invasion and enhances the antitumor capacity of cisplatin via STAT3 pathway in osteosarcoma
- (2019) Binlong Zhong et al. Cell Death & Disease
- The ABC subfamily A transporters: Multifaceted players with incipient potentialities in cancer
- (2019) Michela Pasello et al. SEMINARS IN CANCER BIOLOGY
- Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors
- (2018) Elena Gazzano et al. JOURNAL OF CONTROLLED RELEASE
- Gamma-delta (γδ) T cells: friend or foe in cancer development?
- (2018) Yijing Zhao et al. Journal of Translational Medicine
- Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression
- (2018) Barbara Castella et al. Frontiers in Immunology
- HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma
- (2018) Xin Xiao et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
- (2018) Iris C. Salaroglio et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux
- (2018) Angie M. Torres-Adorno et al. ONCOGENE
- γδ T Lymphocytes: An Effector Cell in Autoimmunity and Infection
- (2018) Carolina Maiumi Shiromizu et al. Frontiers in Immunology
- PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy
- (2017) Iris C. Salaroglio et al. Molecular Cancer
- The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells
- (2017) Barbara Castella et al. Nature Communications
- Assessment of tumor-infiltrating TCRVγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays
- (2017) Marie Tosolini et al. OncoImmunology
- Zoledronic Acid Enhances Vδ2 T-Lymphocyte Antitumor Response to Human Glioma Cell Lines
- (2017) E. Cimini et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial
- (2016) Sophie Piperno-Neumann et al. LANCET ONCOLOGY
- Knockdown of PARP-1 Inhibits Proliferation and ERK Signals, Increasing Drug Sensitivity in Osteosarcoma U2OS Cells
- (2016) Sheng Li et al. ONCOLOGY RESEARCH
- Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors
- (2016) Joanna Kopecka et al. Oncotarget
- Advances in emerging drugs for osteosarcoma
- (2015) Claudia Maria Hattinger et al. EXPERT OPINION ON EMERGING DRUGS
- Conserved and divergent aspects of human T-cell development and migration in humanized mice
- (2015) Joanna Halkias et al. IMMUNOLOGY AND CELL BIOLOGY
- Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells
- (2015) Meng Liu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
- (2015) Giovanni Grignani et al. LANCET ONCOLOGY
- The prognostic landscape of genes and infiltrating immune cells across human cancers
- (2015) Andrew J Gentles et al. NATURE MEDICINE
- Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells
- (2015) Joanna Kopecka et al. Oncotarget
- Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells
- (2015) Micol Rigoni et al. Oncotarget
- Combinatorial Strategies for the Induction of Immunogenic Cell Death
- (2015) Lucillia Bezu et al. Frontiers in Immunology
- Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma
- (2015) Iris Chiara Salaroglio et al. Oncotarget
- Targeting the Achilles Heel of Multidrug-Resistant Cancer by Exploiting the Fitness Cost of Resistance
- (2014) Gergely Szakács et al. CHEMICAL REVIEWS
- Involvement of HIF-1α activation in the doxorubicin resistance of human osteosarcoma cells
- (2014) LAURA RONCUZZI et al. ONCOLOGY REPORTS
- Akt Inhibition Promotes ABCA1-Mediated Cholesterol Efflux to ApoA-I through Suppressing mTORC1
- (2014) Fumin Dong et al. PLoS One
- Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition
- (2013) Giada Gelsomino et al. Molecular Cancer
- Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells
- (2013) Chiara Riganti et al. PLoS One
- Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes
- (2012) Ivana Campia et al. BIOCHEMICAL JOURNAL
- Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances
- (2011) Ehud Segal et al. BIOMATERIALS
- Copy number defects of G1-Cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis
- (2011) Jan J. Molenaar et al. GENES CHROMOSOMES & CANCER
- Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between V 9V 2 T Cells, CD8+ T Cells, Regulatory T Cells, and Dendritic Cells
- (2011) B. Castella et al. JOURNAL OF IMMUNOLOGY
- Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process
- (2010) G. Moriceau et al. CANCER RESEARCH
- New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients
- (2010) Sergio Granados-Principal et al. FOOD AND CHEMICAL TOXICOLOGY
- Self-assembly nanoparticles for the delivery of bisphosphonates into tumors
- (2010) G. Salzano et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells
- (2010) Joanna Kopecka et al. JOURNAL OF CONTROLLED RELEASE
- Targeting Angiogenesis-Dependent Calcified Neoplasms Using Combined Polymer Therapeutics
- (2009) Ehud Segal et al. PLoS One
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now